IDEAS home Printed from https://ideas.repec.org/a/epw/pharma/v5y2025i1id785.html

G-protein Coupled Receptors (GPCRs): A Potential Target of Apigenin as a Novel hACE2 Receptor Specific Therapeutic for Impeding Lung Cancer Considering a Group of Missense and Nonsense Mutations in COVID-19 Patients

Author

Listed:
  • Rasel Ahmed

    (Teesside University, United Kingdom)

  • Sharmin Akter

    (Indiana State University, USA)

  • Fnu Nurunnahar

    (Mawlana Bhashani Science and Technology University, Bangladesh)

  • Sabiha Sultana

    (Illinois State University, USA)

  • Sabbir Hasan

    (Otto Von Guericke University, Germany)

  • Sharmin Ahmed

    (Jashore Medical College, Bangladesh)

  • Md. Al Hasibuzzaman

    (Ningbo University, PR China)

  • Syed Nafis Shadman Ali

    (North South University, Bangladesh)

  • Ramisha Tahsin

    (North South University, Bangladesh)

  • Nasiha Tahsin

    (North South University, Bangladesh)

  • Niloy Das

    (University Bangladesh, Bangladesh)

  • Mohammad Habibur Rahman

    (Bangladesh Agricultural University, Bangladesh)

Abstract

This research investigates the role of mutation cascades in enhancing COVID-19-related lung cancer fatalities, specifically through analyzing mutations in the ACE2 gene associated with SARS-CoV-2 infections. Notably, a natural flavonoid, apigenin, has been identified as a promising hACE2-specific therapeutic. The study involved detailed examinations of 27 mutations (23 missense and four nonsense) and the molecular interactions between apigenin and hACE2, revealing a binding energy of -8.1 Kcal/mol. Various molecular dynamics parameters suggested stable interactions, while the drug-gene interaction analysis demonstrated that 18 GPCR genes could metabolize apigenin, effectively blocking hACE2 and thereby inhibiting S-protein attachment. The findings propose that apigenin could serve as a targeted therapy for COVID-19-induced lung cancer.

Suggested Citation

Handle: RePEc:epw:pharma:v:5:y:2025:i:1:id:785
DOI: 10.24018/ejpharma.2025.5.1.85
as

Download full text from publisher

File URL: https://eu-opensci.org/index.php/pharma/article/view/785
File Function: Abstract page
Download Restriction: no
File URL: https://eu-opensci.org/index.php/pharma/article/download/785/325
File Function: Full text
Download Restriction: no
File URL: https://libkey.io/10.24018/ejpharma.2025.5.1.85?utm_source=ideas
LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
---><---

More about this item

Keywords

;
;
;

JEL classification:

Statistics

Access and download statistics

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:pharma:v:5:y:2025:i:1:id:785. See general information about how to correct material in RePEc.

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

We have no bibliographic references for this item. You can help adding them by using this form .

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/pharma .

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.